Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

32.57

Mkt cap

1.9B

Volume

871K

High

34.14

P/E Ratio

13.49

52-wk high

41.61

Low

31.83

Div yield

N/A

52-wk low

28.14

Pomerantz Law Firm is investigating claims on behalf of investors of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

March 01, 2025 | 3:15 pm

Pomerantz Law Firm is investigating potential securities fraud or unlawful business practices by Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

February 27, 2025 | 2:15 pm

The article discusses whether value investors should consider buying Harmony Biosciences (HRMY) stock, focusing on the Zacks Rank system which emphasizes earnings estimates and revisions.

Portfolio Pulse from

February 26, 2025 | 4:00 pm

Harmony Biosciences Holdings, Inc. (HRMY) reported Q4 earnings of $0.85 per share, surpassing the Zacks Consensus Estimate of $0.74. This marks a significant increase from $0.45 per share a year ago.

Portfolio Pulse from

February 25, 2025 | 3:00 pm

Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating positive sentiment about its earnings prospects, which could lead to a stock price increase.

Portfolio Pulse from

February 24, 2025 | 6:15 pm

Harmony Biosciences received a Refusal to File letter from the FDA for its supplemental new drug application for pitolisant, intended to treat excessive daytime sleepiness in idiopathic hypersomnia. Despite this setback, the company's 2025 net revenue guidance remains unchanged.

Portfolio Pulse from

February 19, 2025 | 1:30 pm

The article compares Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC) to determine which is a better value stock for investors interested in the Medical - Biomedical and Genetics sector.

Portfolio Pulse from

February 17, 2025 | 6:00 pm

Harmony Biosciences (HRMY) is recommended for growth investors due to its above-average financial growth, suggesting potential market outperformance.

Portfolio Pulse from

February 13, 2025 | 7:00 pm

The article discusses whether investors are undervaluing Harmony Biosciences (HRMY) by focusing on the Zacks Rank system, which uses earnings estimates and revisions to identify strong stocks. The article highlights the importance of value, growth, and momentum trends in stock selection.

Portfolio Pulse from

February 05, 2025 | 4:00 pm

Wall Street analysts predict a 28.98% upside for Harmony Biosciences (HRMY) based on average price targets. Positive earnings estimate revisions could support this potential increase.

Portfolio Pulse from

January 31, 2025 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.